Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.49 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.49 |
| ▸ | ITGAL | P20701 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949540 | 1.00 | TRPV1 (0.60) | TRPV1KDM4EHPGDKMT2AAPP | |
| SCHEMBL2953017 | 0.87 | TRPV1 (0.66) | TRPV1KDM4EHPGDKMT2AAPP | |
| SCHEMBL2953018 | 0.87 | TRPV1 (0.66) | TRPV1KDM4EHPGDKMT2AAPP | |
| SCHEMBL9363901 | 0.78 | TRPV1 (0.81) | TRPV1KDM4EHPGDKMT2AAPP | |
| SCHEMBL9364141 | 0.78 | TRPV1 (0.81) | TRPV1KDM4EHPGDKMT2AAPP | |
| SCHEMBL2122045 | 0.76 | TRPV1 (1.00) | TRPV1KDM4EHPGDKMT2AAPP | |
| SCHEMBL2122038 | 0.76 | TRPV1 (1.00) | TRPV1KDM4EHPGDKMT2AAPP | |
| SCHEMBL5699369 | 0.74 | HSD17B2 (0.66) | KDM4EHPGDKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL8077994 | 0.73 | TRPV1 (0.66) | TRPV1KDM4EHPGDKMT2AAPP | |
| SCHEMBL8077987 | 0.73 | TRPV1 (0.66) | TRPV1KDM4EHPGDKMT2AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754886-B2 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | US | disclosed |
| EP-1318978-B1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | ABBOTT LAB (US) | 2006-02-08 | — | — | EP | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | TRPV1 4624/4885KDM4E 1911/4885HPGD 2505/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | TRPV1 4689/4885KDM4E 1563/4885HPGD 2709/4885 |
| US-20090137585-A1 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BCOR | TRPV1 4591/4885KDM4E 1143/4885HPGD 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.